Johnson & Johnson officials said the company was unaware of any reportable adverse events resulting from the use of power morcellators prior to 2013.
FDA officials said the agency didn't receive any reports of adverse outcomes resulting from power morcellation prior to December 2013.
Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA
The House Committee on Energy & Commerce has stepped into a key role in the controversy over power morcellation.
The text of Hooman Noorchashm's Nov. 13 letter to the editor of The Cancer Letter follows. Noorchashm is an assistant professor and cardiac surgeon at Thomas Jefferson University Hospital.
The text of Amy Reed's Nov. 13 letter to Ron Walls, executive vice president and chief operating officer at Brigham & Women's Hospital, follows. Reed is an assistant professor of anesthesia and critical care medicine at the Hospital of the University of Pennsylvania.
The text of Ron Walls's Nov. 10 response to Rep. Mike Fitzpatrick's (R-Pa.) letter follows. Walls is executive vice president and chief operating officer at Brigham & Women's Hospital.
The text of Rep. Mike Fitzpatrick's Nov. 5 letter to Ron Walls, executive vice president and chief operating officer at Brigham & Women's Hospital, follows:
FDA approved Cotellic tablets (cobimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
MICHAEL ZINNER was named CEO and executive medical director of Miami Cancer Institute at Baptist Health South Florida.
THE AMERICAN COLLEGE OF RADIOLOGY and several colorectal cancer care advocacy groups urged Congress to pass the CT Colonography Screening for Colorectal Cancer Act, which would provide Medicare coverage for seniors who choose those screening exams.
